These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24350841)

  • 21. Health economics and cost implications of anxiety and other mental disorders in the United States.
    Rice DP; Miller LS
    Br J Psychiatry Suppl; 1998; (34):4-9. PubMed ID: 9829010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing Costs Using the Treatment Inventory Cost in Psychiatric Patients (TIC-P), TIC-P Mini and TIC-P Midi.
    Kanters TA; Timman R; Zijlstra-Vlasveld MC; Muntingh A; Huijbregts KM; van Steenbergen-Weijenburg KM; Bouwmans CAM; van der Feltz-Cornelis CM; Hakkaart-van Roijen L
    J Ment Health Policy Econ; 2019 Mar; 22(1):15-24. PubMed ID: 30991352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study.
    Carr VJ; Neil AL; Halpin SA; Holmes S; Lewin TJ
    Aust N Z J Psychiatry; 2003 Feb; 37(1):31-40. PubMed ID: 12534654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive Cost of Illness of Three Major Diseases in Japan.
    Matsumoto K; Hanaoka S; Wu Y; Hasegawa T
    J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1934-1940. PubMed ID: 28712721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The costs of social anxiety disorder: the role of symptom severity and comorbidities.
    Stuhldreher N; Leibing E; Leichsenring F; Beutel ME; Herpertz S; Hoyer J; Konnopka A; Salzer S; Strauss B; Wiltink J; König HH
    J Affect Disord; 2014 Aug; 165():87-94. PubMed ID: 24882183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Burden of narcolepsy in Japan: A health claims database study evaluating direct medical costs and comorbidities.
    Kamada Y; Imanishi A; Chiu SW; Yamaguchi T
    Sleep Med; 2024 Feb; 114():119-127. PubMed ID: 38181583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The epidemiology of anxiety disorders: prevalence and societal costs.
    Lépine JP
    J Clin Psychiatry; 2002; 63 Suppl 14():4-8. PubMed ID: 12562112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pediatric Anxiety Disorders: A Cost of Illness Analysis.
    Pella JE; Slade EP; Pikulski PJ; Ginsburg GS
    J Abnorm Child Psychol; 2020 Apr; 48(4):551-559. PubMed ID: 32078089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The economic burden of schizophrenia in Canada.
    Goeree R; O'Brien BJ; Goering P; Blackhouse G; Agro K; Rhodes A; Watson J
    Can J Psychiatry; 1999 Jun; 44(5):464-72. PubMed ID: 10389607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic burden of depression in South Korea.
    Chang SM; Hong JP; Cho MJ
    Soc Psychiatry Psychiatr Epidemiol; 2012 May; 47(5):683-9. PubMed ID: 21526429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generalized anxiety disorder: prevalence, burden, and cost to society.
    Wittchen HU
    Depress Anxiety; 2002; 16(4):162-71. PubMed ID: 12497648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations.
    Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Kurebayashi J
    J Med Econ; 2017 Nov; 20(11):1163-1169. PubMed ID: 28782387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections.
    Matsumoto K; Wu Y; Kitazawa T; Fujita S; Seto K; Hasegawa T
    PLoS One; 2018; 13(6):e0199188. PubMed ID: 29920556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
    Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
    J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The societal cost of schizophrenia in Sweden.
    Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
    J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human and economic burden of generalized anxiety disorder.
    Hoffman DL; Dukes EM; Wittchen HU
    Depress Anxiety; 2008; 25(1):72-90. PubMed ID: 17146763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost of anxiety disorders: impact of comorbidity.
    Souêtre E; Lozet H; Cimarosti I; Martin P; Chignon JM; Adès J; Tignol J; Darcourt G
    J Psychosom Res; 1994; 38 Suppl 1():151-60. PubMed ID: 7799247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost of illness study for adult atopic dermatitis in Japan: A cross-sectional Web-based survey.
    Murota H; Inoue S; Yoshida K; Ishimoto A
    J Dermatol; 2020 Jul; 47(7):689-698. PubMed ID: 32383191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic burden from smoking-related diseases in Thailand.
    Bundhamcharoen K; Aungkulanon S; Makka N; Shibuya K
    Tob Control; 2016 Sep; 25(5):532-7. PubMed ID: 26427527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Household costs of mental health care in Ghana.
    Addo R; Nonvignon J; Aikins M
    J Ment Health Policy Econ; 2013 Dec; 16(4):151-9. PubMed ID: 24526584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.